• Moleculin Biotech closed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML.
• No new results were presented; a comprehensive Part A data readout is planned for Q1 2027.
• Part A enrolled 89 patients, with the cohort expected to split roughly evenly between prior intensive chemotherapy and venetoclax-based regimens.
• The company expects the expanded dataset to clarify efficacy across these patient groups without changing the program’s timeline.
• Blinded trial data continue to show no cardiotoxicity signal, a key potential differentiator versus conventional anthracyclines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290845PRIMZONEFULLFEED9835607) on September 29, 2026, and is solely responsible for the information contained therein.